Founded in 2000, Biogenesi is currently the largest PMA clinical reality in Italy , carrying out over 2400 treatment cycles annually in the Monza, Ponte San Pietro (BG) and Osio Sotto (BG) locations.

Our team is made up of gynecologists and embryologists with long and consolidated experience in reproductive medicine and biology. The medical team also boasts qualified obstetric-gynecological experience.

Our care offering includes most of the ART treatments. In particular, we offer a female fertility preservation service , we have the largest clinical program in Europe for in vitro maturation of oocytes and we are a specialized center for ART treatments in patients with polycystic ovary syndrome.

San Donato Hospital Group Our clinics are integrated into hospital facilities of the San Donato Hospital Group and boast cutting-edge medical and laboratory equipment, as well as a consolidated quality certification system.

NHS Our organization is affiliated with the National Health System . Therefore, the costs of PMA treatments do not burden our patients. Furthermore, access to our healthcare offer does not involve any waiting list .

NHS Biogenesi promotes the progress of PMA by supporting its own research programs , organizing scientific events and collaborating with Italian, European, North American and Asian academic institutions.

 

 

Induction of ovulation
Fertility is sometimes compromised by factors that interfere with the ovarian cycle. If not associated with other causes of infertility, such interferences can be controlled pharmacologically in order to promote conditions compatible with spontaneous conception.
Intrauterine insemination (IUI)
IUI is a simple treatment that is suitable for couples in which the woman's tubes are not compromised and the semen sample is normal. Typically, the woman is given a mild hormone treatment to promote follicular growth and ovulation. The sperm are transferred into the uterus to facilitate their encounter with the egg at the time ovulation is expected to occur.
In vitro maturation of oocytes (IVM)
In cases where the risk of ovarian hyperstimulation syndrome is high or for other reasons for which ovarian stimulation is not indicated, it is possible to collect oocytes completely or almost completely excluding the administration of gonadotropins and obtain oocyte maturation in the laboratory. This also allows for an overall simplification of treatment.
In vitro fertilization (IVF)
IVF involves placing eggs (oocytes) and sperm in a test tube to achieve fertilization. Initially designed to treat cases involving the absence of tubal function, over the years IVF has been applied to various types of infertility ( continued ).
Surgical sperm retrieval
If not present in the seminal fluid, in many cases spermatozoa can be retrieved from the testicle through a minimally invasive surgical procedure. The spermatozoa thus retrieved, even if numerically scarce and not very mobile, can then be injected into the oocytes through ICSI.


 

Ovarian tissue preservation
In women whose ovarian function may be permanently compromised by pathologies or radio- and chemotherapy, portions of ovarian tissue can be surgically removed, cryopreserved for long periods and placed back in the ovary at a later time. The tissue thus reimplanted often guarantees a resumption of the ovarian cycle and sometimes the possibility of spontaneous conception.
ICSI
ICSI differs from IVF only in the way fertilization is achieved, which involves injecting a single sperm into each oocyte. This makes it possible to treat even the most severe cases of male infertility, using sperm present in the seminal fluid or surgically recovered from the testicle.
IMSI
Similar to ICSI, IMSI (Intracytoplasmic Morphologically selected Sperm Injection) consists of the microinjection of a single spermatozoon into the oocyte. However, the spermatozoon to be microinjected is selected according to more rigorous morphological criteria than in ICSI, using a device that allows observation of the male gamete at a magnification of 6600 times. In this way, characteristics of the spermatozoon head (such as shape, size and regularity) that are believed to be an expression of the male gametic quality can be evaluated much more precisely. Although not fully validated, IMSI emerges from numerous studies as a technique capable of increasing the chances of success for couples who have experienced repeated failures with the ICSI technique or for cases in which the quality of the semen sample is seriously compromised (oligo-astheno-teratozoospermia or high degree of fragmentation of the sperm DNA).
Embryo culture to blastocyst stage
Embryos are usually transferred into the uterus on the second or third day of development. Using specific culture techniques, embryos can develop for up to 5-6 days in an extracorporeal environment. This option is not always applicable, but in the most favorable cases it allows the identification of the embryos most suitable for transfer.
Assisted hatching
Embryos are usually transferred into the uterus on the second or third day of development. Using specific culture techniques, embryos can develop for up to 5-6 days in an extracorporeal environment. This option is not always applicable, but in the most favorable cases it allows the identification of the embryos most suitable for transfer.
Semen cryopreservation
Embryos are usually transferred into the uterus on the second or third day of development. Using specific culture techniques, embryos can develop for up to 5-6 days in an extracorporeal environment. This option is not always applicable, but in the most favorable cases it allows the identification of the embryos most suitable for transfer.
Oocyte cryopreservation
Oocytes can be cryopreserved, that is, kept at the temperature of liquid nitrogen (-196°C) for a long period and used at a later time. This allows for the valorization of any supernumerary oocytes or for intervention in cases of fertility preservation.
Embryo cryopreservation
In compliance with current laws and in the interest of women's health, in specific cases cryopreservation and deferred use of embryos in excess of the number required for a single transfer to the uterus is permitted. In this way, multiple pregnancies can be limited or eliminated without compromising the overall efficiency of the treatment.


Learn more